A partnership between the University of Oxford, Earlham Institute (EI), and global pharmaceutical companies Biogen Inc and Boehringer Ingelheim will investigate a promising new drug target for the treatment of schizophrenia.
from News Medical Medical Research News Feed https://ift.tt/3iEmdSj
0 Comments